PMID- 17532722
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20181113
IS  - 1173-2563 (Print)
IS  - 1173-2563 (Linking)
VI  - 25
IP  - 12
DP  - 2005
TI  - Antihypertensive effect of irbesartan and predictors of response in 
      obesity-associated hypertension : a prospective, open-label study.
PG  - 765-76
AB  - BACKGROUND: Obesity-associated hypertension is difficult to treat and puts 
      patients at a substantially increased risk of cardiovascular events. Irbesartan 
      has previously been shown to effectively lower blood pressure (BP) in high-risk 
      groups including patients with type 2 diabetes mellitus or nephropathy, and may 
      therefore also be suitable for the treatment of obesity-associated hypertension. 
      In this study we aimed to: (a) assess the efficacy and tolerability of irbesartan 
      alone and in combination with hydrochlorothiazide in patients with 
      obesity-associated mild-to-moderate hypertension; and (b) investigate 
      patient-associated determinants of poor BP control in this patient group. 
      PATIENTS AND METHODS: This was a 3-month, prospective, open-label, multicentre, 
      phase IV study in 72 479 hypertensive patients in 6989 general practices across 
      Germany. Main outcome measures were BP reduction (primary parameter of 
      effectiveness) and BP response rates after 3 months, as well as adverse events 
      (AEs). Independent predictors of poor control were identified in a multivariate 
      proportional odds model. RESULTS: All of the patients were Caucasian, 50.5% were 
      females, mean age was 62.1 +/- 11.1 years, mean bodyweight was 88.6 +/- 15.4kg, 
      and mean body mass index (BMI) was 30.7 +/- 4.8 kg/m(2). Almost all the patients 
      were overweight or obese (92.3%). From a baseline value of 162/94mm Hg, systolic 
      and diastolic BP were reduced by a mean of -23/-12mm Hg after 3 months. 66.1% of 
      the patients were responders (reduction of diastolic BP >/=10mm Hg), and 48.0% 
      achieved BP normalisation (i.e. <140/90mm Hg). 79% of patients met their 
      individual treatment goals as defined by the treating physician (mean 135/80mm 
      Hg). AEs were reported in only 322 patients (0.4%). Factors requiring special 
      attention in patients not achieving BP control were age (>55 years), high BMI 
      category (>25 kg/m(2)), and increased waist circumference. CONCLUSION: Treatment 
      with irbesartan (+/- hydrochlorothiazide) appeared to be effective and well 
      tolerated in the study population of patients with obesity- associated 
      hypertension. Easily recognisable characteristics allow physicians to identify 
      patients whose BP is likely to be difficult to control.
FAU - Sharma, Arya M
AU  - Sharma AM
AD  - Department of Medicine, McMaster University, Hamilton General Hospital, Hamilton, 
      Ontario, Canada.
FAU - Bramlage, Peter
AU  - Bramlage P
FAU - Kirch, Wilhelm
AU  - Kirch W
LA  - eng
PT  - Journal Article
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
EDAT- 2007/05/30 09:00
MHDA- 2007/05/30 09:01
CRDT- 2007/05/30 09:00
PHST- 2007/05/30 09:00 [pubmed]
PHST- 2007/05/30 09:01 [medline]
PHST- 2007/05/30 09:00 [entrez]
AID - 25123 [pii]
AID - 10.2165/00044011-200525120-00003 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2005;25(12):765-76. doi: 10.2165/00044011-200525120-00003.